These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8360119)

  • 1. In-vitro activity of imipenem and amikacin combinations against resistant Pseudomonas aeruginosa.
    Fujita J; Negayama K; Takigawa K; Yamagishi Y; Yamaji Y; Kawanishi K; Takahara J
    J Antimicrob Chemother; 1993 Jun; 31(6):1007-9. PubMed ID: 8360119
    [No Abstract]   [Full Text] [Related]  

  • 2. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa.
    Gerçeker AA; Otük G
    Chemotherapy; 1995; 41(6):433-6. PubMed ID: 8529433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.
    McGrath BJ; Lamp KC; Rybak MJ
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1931-7. PubMed ID: 8239608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa.
    Gerçeker AA; Gürler B
    J Antimicrob Chemother; 1995 Oct; 36(4):707-11. PubMed ID: 8591946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
    Wilhelm CM; Nunes LS; Martins AF; Barth AL
    Diagn Microbiol Infect Dis; 2018 Oct; 92(2):152-154. PubMed ID: 29891185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Kentepozidis N; Antonopoulou A; Plachouras D; Tsaganos T; Giamarellou H
    Diagn Microbiol Infect Dis; 2005 Feb; 51(2):113-7. PubMed ID: 15698716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of antibiotics against resistant Pseudomonas aeruginosa.
    Fujita J; Negayama K; Takigawa K; Yamagishi Y; Kubo A; Yamaji Y; Takahara J
    J Antimicrob Chemother; 1992 May; 29(5):539-46. PubMed ID: 1365010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K; Ishida A; Chinzei T
    Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.
    Díez Enciso M
    Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):90-2. PubMed ID: 1907544
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.
    Bustamante CI; Drusano GL; Wharton RC; Wade JC
    Antimicrob Agents Chemother; 1987 Apr; 31(4):632-4. PubMed ID: 3111357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
    Yamashiro Y; Ogake N; Takahata M; Minami S
    Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E; Zer Y; Eksi F
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofloxacin interactions with imipenem and amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellou H; Petrikkos G
    Antimicrob Agents Chemother; 1987 Jun; 31(6):959-61. PubMed ID: 3113330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of superinhibitory levels of imipenem and amikacin singly or in combination on Pseudomonas aeruginosa].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1997 Dec; 46(4):155-7. PubMed ID: 9471306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii.
    Fernández-Cuenca F; Martínez-Martínez L; Pascual A; Perea EJ
    Chemotherapy; 2003 May; 49(1-2):24-6. PubMed ID: 12714805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Ansorg R; Müller KD; Wiora J
    Chemotherapy; 1990; 36(3):222-9. PubMed ID: 2110878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftriaxone and amikacin against Pseudomonas aeruginosa.
    Prosser BL; Taylor DB; Cleeland R
    Chemotherapy; 1991; 37(2):93-7. PubMed ID: 1903341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
    Bertrou A; Marty N; Henry S; Agueda L; Chabanon G
    Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.
    Pruekprasert P; Tunyapanit W
    Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1239-42. PubMed ID: 16438151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.